Biodexa plans to initiate a Phase 2 clinical program of tolimidone in Type 1 diabetes, following several preclinical studies demonstrating its role in beta cell survival
Safety profile established in prior human studies of more than 700 patients
https://www.globenewswire.com/news-release/2024/02/07/2825207/0/en/Biodexa-Announces-Allowance-of-U-S-Patent-Covering-Tolimidone.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.